Role of formulation vehicles in taxane pharmacology

被引:260
作者
van Zuylen, L
Verweij, J
Sparreboom, A
机构
[1] Rotterdam Canc Inst, Daniel den Hoed Klin, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam, Netherlands
关键词
Cremophor EL; paclitaxel; Tween; 80; docetaxel; pharmacokinetics;
D O I
10.1023/A:1010618632738
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The non-ionic surfactants Cremophor EL (CrEL) and Tween 80, both used as formulation vehicles of many (anticancer) agents including paclitaxel and docetaxel, are not physiological inert compounds. We describe their biological properties, especially the toxic side effects, and their pharmacological properties, such as modulation of P-glycoprotein activity. In detail, we discuss their influence on the disposition of the solubilized drugs, with focus on CrEL and paclitaxel, and of concomitantly administered drugs. The ability of the surfactants to form micelles in aqueous solution as well as biological fluids (e.g. plasma) appears to be of great importance with respect to the pharmacokinetic behavior of the formulated drugs. Due to drug entrapment in the micelles, plasma concentrations and clearance of free drug change significant leading to alteration in pharmacodynamic characteristics. We conclude with some perspectives related to further investigation and development of alternative methods of administration.
引用
收藏
页码:125 / 141
页数:17
相关论文
共 153 条
  • [51] TWEEN 80 INCREASES PLASMA ADRIAMYCIN CONCENTRATIONS IN MICE BY AN APPARENT REDUCTION OF PLASMA-VOLUME
    HARRISON, SD
    CUSIC, AM
    MCAFEE, SM
    [J]. EUROPEAN JOURNAL OF CANCER, 1981, 17 (04) : 387 - 389
  • [52] HAYES FA, 1985, CANCER TREAT REP, V69, P439
  • [54] Hoffman H., 1984, PHARM Z, V129, P1730
  • [55] Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
    Holmes, FA
    Madden, T
    Newman, RA
    Valero, V
    Theriault, RL
    Fraschini, G
    Walters, RS
    Booser, DJ
    Buzdar, AU
    Willey, J
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2713 - 2721
  • [56] HORTOBAGYI GN, 1997, SEMIN ONCOL, V24
  • [57] ANAPHYLACTOID REACTIONS ASSOCIATED WITH PARENTERAL CYCLOSPORINE USE - POSSIBLE ROLE OF CREMOPHOR-EL
    HOWRIE, DL
    PTACHCINSKI, RJ
    GRIFFITH, BP
    HARDESTY, RJ
    ROSENTHAL, JT
    BURCKART, GJ
    VENKATARAMANAN, R
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (06): : 425 - 427
  • [58] Pharmacokinetics of paclitaxel and carboplat dose-escalating and dose-sequencing study in with non-small-cell long cancer
    Huizing, MT
    Giaccone, G
    vanWarmerdam, LJC
    Rosing, H
    Bakker, PJM
    Vermorken, JB
    Postmus, PE
    vanZandwijk, N
    Koolen, MGJ
    Huinink, WWTB
    vanderVijgh, WJF
    Bierhorst, FJ
    Lai, A
    Dalesio, O
    Pinedo, HM
    Veenhof, CHN
    Beijnen, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 317 - 329
  • [59] PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS
    HUIZING, MT
    KEUNG, ACF
    ROSING, H
    VANDERKUIJ, V
    HUININK, WWT
    MANDJES, IM
    DUBBELMAN, AC
    PINEDO, HM
    BEIJNEN, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) : 2127 - 2135
  • [60] COMPLEMENT-MEDIATED REACTIONS TO DIAZEPAM WITH CREMOPHOR AS SOLVENT (STESOLID MR)
    HUTTEL, MS
    OLESEN, AS
    STOFFERSEN, E
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1980, 52 (01) : 77 - 79